BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Accellta

Growing Stem Cells in Suspension Bioreactors with Dr. Angel of Accellta

July 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Exclusive Q&A Interview with Dr. Itzchak Angel, CEO of Israeli Stem Cell Company, Accellta

Accellta IsraelDr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]

Filed Under: HSCs, Interviews, iPS Cells, MSCs, Stem Cells Tagged With: Accellta, interview, stem cells

Interview with Accellta’s Intellectual Property (IP) Officer, Eran Cohen

July 23, 2017 By Cade Hildreth (CEO) Leave a Comment

Exclusive Q&A Interview with Dr. Itzchak Angel, CEO of Israeli Stem Cell Company, Accellta

Accellta IsraelThis is an exciting addition to my recent interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.

[Read more…]

Filed Under: Interviews, Stem Cells Tagged With: Accellta, Dr. Itzchak Angel, Eran Cohen, interview, market news, stem cells

High-Volume 3D Printing of Living Stem Cells – Proof-of-Concept Established by Nano Dimension and Accellta

May 25, 2016 By Cade Hildreth (CEO) Leave a Comment

High-Volume 3D Printing of Living Stem Cells – Proof-of-Concept Established by Nano Dimension and Accellta - Depositphotos_60459385_m-2015.jpg

Recently, I had the honor of interviewing Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta Ltd. Accellta is introducing a paradigm shift to the stem cell marketplace by quickly, efficiently, and cost-effectively growing massive quantities of clinical grade cells in xeno-free, feeder-free culture. Based in Haifa, Israel, Dr. Angel leads a team of executives and researches who are world-renowned experts at growing stem cells in suspension.

In major news released today, Nano Dimension Ltd. announced it has successfully “lab-tested a proof of concept 3D bioprinter for stem cells” in collaboration with Accellta Ltd. Nano Dimension Ltd. specializes in 3D printing systems, while Accellta uses 3D bioreactors to grow large numbers of cells in suspension. Specifically, Accellta can increase a cell population from 1 million cells to 10 billion cells in two weeks with an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Using traditional adherent culture, it would cost of $150,000 and take 40 to 50 days. [Read more…]

Filed Under: Stem Cells Tagged With: 3D printing, Accellta, Nano Dimension, stem cells

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

April 24, 2016 By Cade Hildreth (CEO) Leave a Comment

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

This was a major week in the stem cell sector, with significant announcements released by STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, and more. The FDA also released significant news pertaining to a public hearing that will  address the regulation of stem cells within the United States. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: Accellta, CardioCell, Cellect Biomed Ltd., STEMCELL Technologies

Israel Continues to Cultivate Stem Cell Innovation as Cellect and Accellta Enter Into Collaborative Agreement

April 19, 2016 By Cade Hildreth (CEO) Leave a Comment

Israel Continues to Cultivate Stem Cell Innovation as Cellect and Accellta Enter Into Collaborative Agreement

In major news today, Cellect Biomed Ltd. and Accellta announced that they have signed an agreement to evaluate Cellect’s apoptotic induction based technology in combination with Accellta’s stem cell culturing technologies. Cellect Biomed Ltd. is headquartered in Tel Aviv, while Accellta is headquartered in Haifa, Israel.

Accellta is a fascinating stem cell company that can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture, by utilizing methods of growing the cells in suspension. Specifically, the company can increase a cell population from 1 million cells to 10 billion cells in two weeks with a bi-weekly change of media and an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Using traditional adherent culture, this would take about 70 liters of medium and an overall cost of $150,000, because it would take 40 to 50 days to do the expansion. [Read more…]

Filed Under: Press Releases, Stem Cells Tagged With: Accellta, Cellect, press release, stem cells

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.